Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts

The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a variety of preclinical models through the activation of the STAT3 (signal transducer and activator of transcription 3) signaling pathway. However, the proportion of breast cancers sensitive to anti-IL-6 therapies is not...

Descripción completa

Detalles Bibliográficos
Autores principales: Morancho, Beatriz, Zacarías-Fluck, Mariano, Esgueva, Antonio, Bernadó-Morales, Cristina, Cosimo, Serena Di, Prat, Aleix, Cortés, Javier, Arribas, Joaquín, Rubio, Isabel T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356531/
https://www.ncbi.nlm.nih.gov/pubmed/27602583
http://dx.doi.org/10.18632/oncotarget.11815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356531/
https://www.ncbi.nlm.nih.gov/pubmed/27602583
http://dx.doi.org/10.18632/oncotarget.11815

Ejemplares similares